

January 25, 2023

To

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Tel: 022 - 2272 1233 /4 Fax: 022 - 22721919

Ref: Aragen Life Sciences Private Limited

Scrip Code: 973783 ISIN: INE483I07010

Sub: Disclosure of information pursuant to Regulation 51 (2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Ma'am,

Pursuant to Regulation 51 (2) read with Part B of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Company's "Policy for fair disclosure of Unpublished Price Sensitive Information", we hereby intimate that, subject to the approval of the shareholders as applicable, the Board of Directors of the Company at their meeting held on 25th January 2023, considered, and approved the following, among other matters:

- 1) Conversion of the Company from a Private Limited to a Public Limited Company.
- 2) Issuing of Two Bonus Equity Shares of Rs. 10/- each to the equity shareholders of the Company for every One equity share of face value of Rs. 10/- held in the Company, by capitalising the free reserves, Securities Premium account or such other accounts as may be permissible to be utilized for the purpose.
- 3) Appointment of Mr. Manmahesh Kantipudi, the existing Director & CEO of the Company, as the Whole-time Director of the Company, to hold the office for a period of Five (5) years from 25th January 2023 to 24th January 2028.
- 4) Appointment of Mr. Manmahesh Kantipudi, Whole-time Director, Mr. Sachin Anand Dharap, Chief Financial Officer and Mr. Ramakrishna Kasturi, Company Secretary, of the Company as the whole-time Key Managerial Personnel of the Company, under Section 203 of the Companies Act, 2013.

Please take on your records.

For Aragen Life Sciences Private Limited

KASTURI Digitally signed by KASTURI RAMAKRISH RAMAKRISHNA Date: 2023.01.25 21:52:26 +05'30'

Ramakrishna Kasturi

Company Secretary & Compliance Officer